Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.

IF 3 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-08-16 DOI:10.4155/tde-2023-0045

Paul Zarogoulidis, Dimitris Petridis, Haidong Huang, Chong Bai, Panagoula Oikonomou, Christina Nikolaou, Dimitris Matthaios, Eleni-Isidora Perdikouri, Vasilis Papadopoulos, Savvas Petanidis, Christoforos Kosmidis, Charalampos Charalampidis, Wolfgang Hohenforst-Schmidt, Nikos Kougkas, Chrysanthi Sardeli

{"title":"Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.","authors":"Paul Zarogoulidis, Dimitris Petridis, Haidong Huang, Chong Bai, Panagoula Oikonomou, Christina Nikolaou, Dimitris Matthaios, Eleni-Isidora Perdikouri, Vasilis Papadopoulos, Savvas Petanidis, Christoforos Kosmidis, Charalampos Charalampidis, Wolfgang Hohenforst-Schmidt, Nikos Kougkas, Chrysanthi Sardeli","doi":"10.4155/tde-2023-0045","DOIUrl":null,"url":null,"abstract":"Aim: Idiopathic pulmonary fibrosis is a rare disease with few efficient drugs in the market. The consequences of this disease are mainly respiratory failure and pulmonary hypertension. Materials & methods: In our experiment we used the drugs pirfenidone, nintetanib and macitentan. We performed nebulization experiments with three jet nebulizers and three ultrasound nebulizers with different combinations of residual cup designs, and residual cup loadings in order to identify which combination produces droplets of less than 5 μm in mass median aerodynamic diameter. Results: Pirfenidone versus nintetanib had smaller droplet size formation at both inhaled technologies (1.37 < 2.23 and 1.92 < 3.11, jet and ultrasound respectively). Discussion: Pirfenidone and nintetanib can be administered as aerosol in any type of nebulization system.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"491-498"},"PeriodicalIF":3.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/tde-2023-0045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Idiopathic pulmonary fibrosis is a rare disease with few efficient drugs in the market. The consequences of this disease are mainly respiratory failure and pulmonary hypertension. Materials & methods: In our experiment we used the drugs pirfenidone, nintetanib and macitentan. We performed nebulization experiments with three jet nebulizers and three ultrasound nebulizers with different combinations of residual cup designs, and residual cup loadings in order to identify which combination produces droplets of less than 5 μm in mass median aerodynamic diameter. Results: Pirfenidone versus nintetanib had smaller droplet size formation at both inhaled technologies (1.37 < 2.23 and 1.92 < 3.11, jet and ultrasound respectively). Discussion: Pirfenidone and nintetanib can be administered as aerosol in any type of nebulization system.

查看原文本刊更多论文

吸入宁替尼、吡非尼酮和马西坦治疗肺纤维化：一项实验室实验。

目的：特发性肺纤维化是一种罕见的疾病，市场上有效药物很少。这种疾病的后果主要是呼吸衰竭和肺动脉高压。材料与方法：本实验采用吡非尼酮、茚替他尼和马西坦三种药物。我们用三个射流雾化器和三个超声雾化器进行了雾化实验，这些雾化器具有不同的残余杯设计和残余杯载荷组合，以确定哪种组合产生的液滴质量中值空气动力学直径小于5μm。结果：在两种吸入技术中，吡非尼酮和尼替他尼的液滴形成较小（1.37讨论：吡非尼和尼替替他尼可以在任何类型的雾化系统中作为气雾剂给药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.